Trichotillomania (Hair-Pulling Disorder): How It Is Diagnosed, What Treatment Has Trial Evidence, and Whether the Hair Grows Back
3,347 words·Compiled from cited medical literature·Not medical advice
On this page 9 sections
Who This Is For#
This guide is for you if:
- You pull out your hair, or suspect someone you care about does
- You have irregular patches containing hairs of many different lengths
- You have been told you might have alopecia areata, but the patches are not round and smooth
- You want to know which treatments have been tested in trials
- You have stopped pulling and want to know whether the hair returns
This guide is NOT for you if:
- Your patches are round, smooth, and fully bald with no stubble: see Alopecia Areata: Types, Treatment, and Outlook
- The loss follows tight braids, weaves, or ponytails: see Traction Alopecia: Prevention and Treatment
- Your scalp is painful, red, scaly, or shiny and scarred: see When to See a Dermatologist for Hair Loss: Red Flags
What Trichotillomania Is#
A body-focused repetitive behavior, not a habit you should be able to "just stop"#
Trichotillomania is the repeated pulling out of one's own hair, most often from the scalp but also from eyebrows and eyelashes. Modern classifications place it with the obsessive-compulsive and related disorders rather than treating it as a bad habit. The ICD-11 grouping emphasizes "repetitive unwanted thoughts and associated behaviours" and includes trichotillomania among the body-focused repetitive behavior disorders, a placement the authors describe as "supported by neuroimaging and genetic evidence" [3].
It rarely travels alone. In a survey-based analysis, 70% of hair-pulling participants "reported additional BFRBs, predominantly skin-picking and nail-biting" [4], and higher counts of these behaviors tracked with "increased focused hair-pulling, depression, anxiety, stress, and functional impairment" [4].
How common it is, when it starts, and who gets it#
A survey of 10,169 U.S. adults found that 1.7% had current trichotillomania, "with no significant gender differences" [1]. An earlier survey of 2,534 college freshmen found "a 0.6% lifetime prevalence of DSM-III-R trichotillomania for both male and female respondents" [2], plus hair pulling with visible hair loss in 1.5% of males and 3.4% of females who did not meet full criteria [2]. The two surveys used different criteria in different populations, so the figures are not comparable.
The adult survey reported that "The mean age of onset for trichotillomania was 17.7 years," with females starting earlier, at 14.8 years, than males, at 19.0 years [1]. Adolescence is the typical window, and the absence of a prevalence gap between men and women [1] cuts against the assumption that this is a women's condition — the community survey found no significant difference in prevalence between men and women [1], even though onset came earlier in females.
How a Dermatologist Tells It Apart from Alopecia Areata#
Trichotillomania patches look irregular rather than round, and — the key sign — they are not truly bald. Inside the patch is stubble of many different lengths, because hairs broke off wherever the fingers could grip. Alopecia areata patches are typically smooth, round, and empty.
What trichoscopy shows#
Trichoscopy — dermoscopy of the scalp, "a simple and easy-to-perform technique that has been utilized for diagnosis and management" of hair and scalp disorders [13] — is the most useful test here. A comparative series of trichotillomania, alopecia areata, and tinea capitis reported the characteristic trichotillomania features as "irregularly broken hairs (44/44; 100% of patients), v-sign (24/44; 57%), flame hairs (11/44; 25%), hair powder (7/44; 16%) and coiled hairs (17/44; 39%)" [8]. (The V-sign is the appearance of two hairs from one follicular unit broken at the same length.)
A systematic review pooled these across studies and added specificity:
| Trichoscopy feature | Prevalence in trichotillomania | Specificity |
|---|---|---|
| Trichoptilosis (split ends) | 57.5% | 97.5% |
| V-sign | 50.4% | 99% |
| Hook hairs | 43.1% | 100% |
| Flame hairs | 37.1% | 96.5% |
| Coiled hairs | 36.8% | 99.6% |
| Tulip hairs | 36.4% | 89.6% |
| Hair powder | 35.6% | 97.9% |
Source: systematic review calling trichoscopy "a reliable new diagnostic method" for standard clinical assessment [9]. Only trichoptilosis (57.5%) and the V-sign (50.4%) appear in more than half of patients, but several features are close to specific — hook hairs reached 100% specificity and the V-sign 99% [9] — so the diagnosis is built from a combination.
Alopecia areata has its own signature: "yellow dots, short vellus hairs, and black dots" are common there, though "There is no pathognomonic trichoscopic marker" [11]. A comparative study in skin of color found "Exclamation mark and tapered hairs" significantly more often in alopecia areata and "broken hairs and trichoptilosis" in trichotillomania, noting that "Even though there is an overlap of trichoscopic features in AA and TTM," particular combinations separate them [10].
When a biopsy is used#
Most cases do not need one. When the picture is ambiguous — or a child cannot or will not confirm the behavior — an older review recommends "punch biopsy of the affected scalp" [15]. What extraction leaves behind is suggestive, not conclusive: a histopathology series found pigmented casts in "72% of alopecia areata cases, 100% of trichotillomania cases" but concluded they "can be observed in biopsies of different hair disorders, but they are not specific for the diagnosis" [14].
Sudden patchy loss, a painful scalp, shiny scarred skin, or hair loss with systemic symptoms belongs with a dermatologist; the red flags guide covers what needs prompt attention.
What the Treatment Evidence Shows#
Behavioral therapy has the strongest trial support#
Habit reversal training teaches you to notice the urge and the early movement, then substitute a competing response. It has the clearest randomized evidence.
In a preliminary randomized controlled trial in youth, habit reversal training versus treatment as usual produced "76% classified as treatment responders compared to 21% in the control group" [16], with improvements that "persisted at follow-up assessments" [16]. In adults, a controlled trial of acceptance and commitment therapy plus habit reversal against a waitlist produced "significant reduction in hair pulling severity, impairment ratings, and hairs pulled," with reduced anxiety and depression, "sustained at three-month follow-up" [17].
Both trials are small. Even so, this is the only category with two randomized trials pointing the same way, and the strongest evidence available for any trichotillomania treatment.
N-acetylcysteine worked in adults and failed in the pediatric trial#
In a double-blind, placebo-controlled trial in adults, "Fifty-six percent of patients 'much or very much improved' with N-acetylcysteine use compared with 16% taking placebo," and it was "well-tolerated with no adverse events reported" [18]. A placebo-controlled add-on trial in children and adolescents found "no significant difference between N-acetylcysteine and placebo" on primary or secondary measures, with "both groups improved over time regardless of treatment" [19]; those authors recommended behavioral therapy as first-line in youth [19]. The adult result does not transfer to a child, and anyone weighing this — supplement versions included — should raise it with the clinician managing the condition.
SSRIs, olanzapine, and clomipramine#
Two Cochrane reviews have examined drug treatment and stayed restrained. The 2021 update found "Insufficient evidence from meta-analysis to confirm or refute the efficacy of any agent," while noting "Preliminary evidence suggests there may be beneficial treatment effects for N-acetylcysteine, clomipramine and olanzapine in adults based on four trials, albeit with relatively small sample sizes" [20]. The earlier review concluded that "No particular medication class definitively demonstrates efficacy" and that "SSRIs and naltrexone showed no strong evidence of treatment effects" [21]. The distinction matters: for SSRIs the evidence is weak or absent, which is not the same as proof that they do nothing. No SSRI-specific meta-analysis has pooled an effect size for trichotillomania.
Olanzapine has one small randomized trial, in which "11 of 13 participants (85%) in the olanzapine group and 2 of 12 (17%) in the placebo group were considered responders" [22] — an antipsychotic, prescribed and monitored by a psychiatrist, on one trial that settles nothing.
Clomipramine was compared with desipramine in a small crossover trial of adult women published in 1989: "The severity of symptoms (mean base-line score, 15.9 +/- 3.8) was reduced more by clomipramine (10.6 +/- 6.4)" [23]. That trial is old and tiny. Clomipramine is not FDA-approved for trichotillomania — in pediatric patients its approved indication is obsessive-compulsive disorder, ages 10-17 — and its label carries a boxed warning that "Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults" [24].
None of this is a reason to start anything: a psychiatrist or physician decides what is appropriate and safe alongside everything else you take.
Does the Hair Grow Back?#
Mechanical damage, so regrowth is the rule — but no trial has measured it#
Usually, yes. One review describes trichotillomania as "a form of traction alopecia resulting from repetitive and compulsive hair pulling" [12]. The damage is mechanical: follicles are injured, not destroyed, so once pulling stops they generally re-enter the growth cycle, as in early traction alopecia.
Two honest caveats. No trial has measured regrowth after pulling stops, so no one can say what proportion returns or how long it takes. And years of pulling at one spot can scar the follicle permanently; scarred follicles do not regrow, and how often that happens has not been quantified. A patch that stays smooth and shiny long after you stopped is for a dermatologist to examine, not to wait out. Same-lighting photographs taken at fixed intervals tell you more than daily mirror checks; the photo tracking guide explains how.
The Overlap with Anxiety, Depression, and Skin Picking#
Comorbidity is the rule, but pulling is not a stress thermometer#
Co-occurring conditions are the rule. In the adult community survey, "79% of people with trichotillomania had one or more mental health comorbidities," including anxiety, depression, OCD, PTSD, and ADHD [1].
Skin picking sits closest. A comparison found "substantial phenomenological similarities in demographics, psychiatric comorbidity, and personality characteristics" between the two, while noting "Dissociative symptoms may be more common in trichotillomania than in pathological skin-picking" [6]. The protocols overlap: a randomized trial of a cognitive behavioral protocol first developed for trichotillomania, applied to skin picking, reported "high remission rates (individual 63%, group 52%)" [7] — evidence the approach transfers, not a trichotillomania result.
One nuance contradicts a common assumption. A meta-analysis across obsessive-compulsive and related disorders found "Grooming disorders have relatively limited associations with negative emotionality," with hair pulling disorder showing a correlation of r = 0.28 compared to stronger correlations in compulsive disorders like OCD (r = 0.44) [5]. Pulling is not a stress thermometer; plenty of people pull while calm, bored, or absorbed. Stress may well be a trigger — see the stress-related hair loss guide — but reducing it alone should not be expected to stop pulling.
Finding Help, and Why Shame Is the Real Obstacle#
Two clinicians, doing different jobs#
This is a treatable condition, with randomized trial evidence behind habit reversal training [16][17]. Embarrassment is a common reason people never raise the pulling with a clinician: the patches go behind hats, hairstyles and makeup for years, and the scalp gets examined without the cause ever being mentioned. The cost is misdiagnosis, pointless topical treatments, and years of avoidable distress. Pulling is not weakness or a character flaw; it is a recognized disorder with randomized trial evidence behind a treatment [16][17].
They do different jobs:
- A mental health professional — psychologist, psychiatrist, or therapist — for the behavior. Ask whether they use habit reversal training or a comparable protocol for body-focused repetitive behaviors, since that is the approach with trial support [16][17]. A psychiatrist or physician also decides whether any medication is appropriate.
- A dermatologist for the scalp: to confirm the diagnosis with trichoscopy, rule out alopecia areata and tinea capitis [8][10], and assess whether any area looks scarred.
What lowers the barrier: write the word "trichotillomania" down and hand it over if saying it is too hard, and bring photographs of the patches at their worst. A clinician who sees hair disorders has seen this before.
Frequently Asked Questions#
How does a dermatologist tell it apart from alopecia areata?#
Mostly trichoscopy. Irregularly broken hairs appeared in 44 of 44 patients in one series, with the V-sign in 57% and flame hairs in 25% [8]; across studies, hook hairs reached 100% specificity and the V-sign 99% [9]. Exclamation-mark and tapered hairs point to alopecia areata instead [10][11].
What treatment has the best evidence?#
Habit reversal training. In a randomized trial in youth, 76% were responders versus 21% of controls [16]; in adults, acceptance and commitment therapy plus habit reversal reduced pulling severity, sustained at three-month follow-up [17]. For medication, a Cochrane review found insufficient evidence to confirm or refute any agent [20].
Does N-acetylcysteine work?#
In adults, one placebo-controlled trial reported fifty-six percent much or very much improved on N-acetylcysteine versus 16% on placebo [18]. In children and adolescents, a placebo-controlled trial found no significant difference, both groups improving over time [19]. The adult result does not carry over to children, and whether to try it is a clinician's call.
Do SSRIs help?#
The evidence is weak. Cochrane reviews concluded that no medication class definitively demonstrates efficacy and that SSRIs showed no strong evidence of treatment effects [21], and the 2021 update found insufficient evidence to confirm or refute any agent [20]. That is not proof they do nothing; an SSRI may still be prescribed for co-occurring anxiety or depression.
Will my hair grow back if I stop pulling?#
Usually. The damage is mechanical, described as a form of traction alopecia [12], and pulled follicles are injured rather than destroyed, so hair generally returns once pulling stops. No trial has measured regrowth rates, so no honest timeline can be quoted. Long-standing pulling at one site can occasionally scar permanently.
Related Resources#
- Alopecia Areata: Types, Treatment, and Outlook
- Traction Alopecia: Prevention and Treatment
- When to See a Dermatologist for Hair Loss: Red Flags
- Scarring Alopecia Types and Management: Complete Guide
- Emotional Impact of Hair Loss: Support Guide for Women
- Stress-Related Hair Loss: Complete Recovery Guide
- Telogen Effluvium: Causes and Recovery Timeline
- Tracking Hair Loss Progress: Photo Guide
Medical Disclaimer
This guide is educational only and is not a substitute for assessment by a dermatologist, psychiatrist, physician, or therapist; it has not been medically reviewed. Nothing here is a recommendation to start, stop, or change any medication. N-acetylcysteine, clomipramine, olanzapine, and SSRIs appear because they have been tested in trials, not because they are advised; a psychiatrist or physician decides. Clomipramine is not FDA-approved for trichotillomania, and its label carries a boxed warning that "Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults" [24]. That label also contraindicates an MAOI used for psychiatric disorders taken with clomipramine, or within 14 days of stopping it, because of serotonin syndrome risk, as it does starting it in a patient taking linezolid or intravenous methylene blue [24]. Olanzapine is an antipsychotic carrying its own risks. Sudden patchy hair loss, scalp pain, redness, scaling, a shiny scarred appearance, or hair loss with systemic symptoms should be assessed by a dermatologist rather than attributed to pulling. If you are having thoughts of harming yourself, contact a clinician or your local emergency service immediately.
References
- Grant JE, Dougherty DD, Chamberlain SR. Prevalence, gender correlates, and co-morbidity of trichotillomania. Psychiatry Res 2020. PMID 32334275.
- Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry 1991. PMID 1938977.
- Stein DJ, Kogan CS, Atmaca M, et al. The classification of Obsessive-Compulsive and Related Disorders in the ICD-11. J Affect Disord 2016. PMID 26590514.
- Stein DJ, Flessner CA, Franklin M, Keuthen NJ, Lochner C, Woods DW. Is trichotillomania a stereotypic movement disorder? An analysis of body-focused repetitive behaviors in people with hair-pulling. Ann Clin Psychiatry 2008. PMID 19034750.
- Snorrason I, Kuckertz JM, Swisher VS, Pendo K, Rissman AJ, Ricketts EJ. Hair pulling disorder and skin picking disorder have relatively limited associations with negative emotionality: A meta-analytic comparison across obsessive-compulsive and related disorders. J Anxiety Disord 2023. PMID 37499420.
- Lochner C, Simeon D, Niehaus DJ, Stein DJ. Trichotillomania and skin-picking: a phenomenological comparison. Depress Anxiety 2002. PMID 11891999.
- Xavier ACM, de Souza CMB, Flores LHF, et al. Skin picking treatment with the Rothbaum cognitive behavioral therapy protocol: a randomized clinical trial. Braz J Psychiatry 2020. PMID 32401873.
- Rakowska A, Slowinska M, Olszewska M, Rudnicka L. New trichoscopy findings in trichotillomania: flame hairs, V-sign, hook hairs, hair powder, tulip hairs. Acta Dermatovenerol Croat 2014. PMID 24096547.
- Kaczorowska A, Rudnicka L, Stefanato CM, Waskiel-Burnat A, Warszawik-Hendzel O, Olszewska M, Rakowska A. Diagnostic Accuracy of Trichoscopy in Trichotillomania: A Systematic Review. Acta Dermatovenerol Croat 2021. PMID 34184065.
- Mani S, Raut A, Neema S, et al. Trichoscopy in Alopecia Areata and Trichotillomania in Skin of Colour: A Comparative Study. Indian J Dermatol 2023. PMID 37151271.
- Waskiel A, Rakowska A, Sikora M, Olszewska M, Rudnicka L. Trichoscopy of alopecia areata: An update. J Dermatol 2018. PMID 29569271.
- Martin JM, Montesinos E, Cordero P, Gonzalez V, Ramon D. Trichoscopy features of trichotillomania. Pediatr Dermatol 2019. PMID 30746759.
- Torres F, Tosti A. Trichoscopy: an update. G Ital Dermatol Venereol 2014. PMID 24566568.
- Miteva M, Romanelli P, Tosti A. Pigmented casts. Am J Dermatopathol 2014. PMID 23823025.
- Muller SA. Trichotillomania. Dermatol Clin 1987. PMID 3301116.
- Rahman O, McGuire J, Storch EA, Lewin AB. Preliminary Randomized Controlled Trial of Habit Reversal Training for Treatment of Hair Pulling in Youth. J Child Adolesc Psychopharmacol 2017. PMID 28005403.
- Woods DW, Wetterneck CT, Flessner CA. A controlled evaluation of acceptance and commitment therapy plus habit reversal for trichotillomania. Behav Res Ther 2006. PMID 16039603.
- Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009. PMID 19581567.
- Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry 2013. PMID 23452680.
- Hoffman J, Williams T, Rothbart R, Ipser JC, Fineberg N, Chamberlain SR, Stein DJ. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev 2021. PMID 34582562.
- Rothbart R, Amos T, Siegfried N, Ipser JC, Fineberg N, Chamberlain SR, Stein DJ. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev 2013. PMID 24214100.
- Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2010. PMID 20441724.
- Swedo SE, Leonard HL, Rapoport JL, Lenane MC, Goldberger EL, Cheslow DL. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 1989. PMID 2761586.
- ANAFRANIL (clomipramine hydrochloride) capsule prescribing information, SpecGx LLC. DailyMed set id 4074b555-7635-41a9-809d-fae3b3610059.
When this guide changes, hear about it
Hair-loss advice ages badly. A trial lands, a dose recommendation shifts, or a figure we published turns out to be wrong — and this page changes. Leave an address and you get told when that happens to a guide you read.